23:58 , Feb 28, 2019 |  BC Innovations  |  Emerging Company Profile

Gotham’s RNA utility belt

Gotham Therapeutics Corp., the newest comer to the RNA epigenetics party, delves into the atomic-level biophysical properties of RNA-modifying enzymes to accelerate its small molecule discovery programs for cancer and other diseases. RNA epigenetics is...
14:04 , Feb 12, 2019 |  BC Innovations  |  Translation in Brief

Storm’s RNA modification software

Storm Therapeutics Ltd. has created an algorithm to extend the use of mass spectrometric data to RNA epigenetics. Making it open source, the company plans to put the algorithm in as many hands as possible...
21:45 , Oct 12, 2018 |  BioCentury  |  Finance

Versant seizes the RNA moment

As the RNA space continues to heat up, Versant Ventures opted out of companies looking to modify RNA directly, and instead seeded and launched RNA epigenetics company Gotham Therapeutics. Versant co-led Gotham’s $54 million series...
13:56 , Sep 20, 2018 |  BC Extra  |  Preclinical News

RNA-modifying enzyme loops mRNA to increase oncogene translation

Boston Children's Hospital researchers showed interaction between a translation factor and RNA-modifying enzyme could enhance oncogene translation by circularizing mRNA, suggesting that disrupting the protein-protein interaction could help treat cancer. At least two companies --...
19:08 , May 18, 2018 |  BC Week In Review  |  Financial News

RNA epigenetics company Accent raises $40M series A

RNA epigenetics company Accent Therapeutics Inc. (Lexington, Mass.) debuted with a $40 million series A co-led by The Column Group and Atlas Venture, with participation from EcoR1 Capital. Accent’s preclinical assets are designed to treat...
09:12 , May 18, 2018 |  BC Extra  |  Financial News

Accent targeting RNA-modifying proteins with $40M series A

RNA epigenetics company Accent Therapeutics Inc. (Lexington, Mass.) debuted with a $40 million series A co-led by The Column Group and Atlas Venture, with participation from EcoR1 Capital. Accent’s preclinical assets are designed to treat...
09:09 , May 18, 2018 |  BioCentury  |  Emerging Company Profile

Accent on RNA

With its debut Friday with a $40 million series A, Accent Therapeutics Inc. became the second disclosed newco to jump into the nascent arena of RNA epigenetics. The biotech has identified enzymes it believes drive...